IGHE and Increased total eosinophil count: The anti-IgE monoclonal omalizumab reduces airway eosinophilia but has no effect on bronchial hyper-responsiveness [14], whereas the anti-TNF monoclonal etanercept reduces hyper-responsiveness but has no effect on airway inflammation [15].